Addyi Regrets? Not From FDA, Likely So For Valeant
This article was originally published in Scrip
In a somewhat rare move, FDA officials took to the New England Journal of Medicine this week to give their perspective about why the agency this past August finally gave in and approved Sprout Pharmaceuticals Inc.'s controversial female libido-boosting pill Addyi (flibanserin) – describing the evaluation of the product as "challenging."
Register for our free email digests: